Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma-Reference-Cited by-同舟云学术

Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma

Published:2018-10-16 Issue:1 Volume:8 Page:e1525243
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Park Junseong¹^ORCID,Kim Chang Gon²,Shim Jin-Kyoung¹,Kim Jong Hoon²,Lee Hoyoung³,Lee Jae Eun¹,Kim Min Hwan²,Haam Keeok⁴,Jung Inkyung⁴,Park Su-Hyung²,Chang Jong Hee¹^ORCID,Shin Eui-Cheol²^ORCID,Kang Seok-Gu¹^ORCID

Affiliation:

1. Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

2. Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea

3. Biomedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, Republic of Korea

4. Department of Biological Sciences, KAIST, Daejeon, Republic of Korea

Funder

Ministry of Education, Science and Technology

Ministry of Health and Welfare

Ministry of Science, ICT and Future Planning

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1525243

Reference32 articles.

1. Cancer statistics, 2018

2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

3. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients

4. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

5. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

2. Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds;Cell Death & Disease;2024-08-15

3. Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models;Cancers;2024-07-24

4. In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development;Neuro-Oncology;2024-07-11

5. Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways;Cancer Immunology Research;2024-06-17